Sanity Group

The Sanity Group has set itself the goal of improving people's quality of life through the meaningful use of cannabinoids and the use of the endocannabinoid system. The focus is on cannabinoid-based medicines and consumer goods. In order to harness the full potential of cannabis, Sanity Group invests in basic research on the cannabis plant and its active ingredients as well as in specific areas of application. The Sanity Group, which was founded in Berlin in 2018, includes Vayamed and avaay Medical (medical cannabis), vaay (lifestyle) and Grashaus Projects (Genusscannabi's pilot project Switzerland). In addition, Sanity Group also has a stake in the finished drug company Endosane Pharmaceuticals. The Sanity Group operates a production plant for cannabis extracts near Frankfurt am Main. Sanity Group Switzerland AG is a subsidiary of Sanity Group GmbH and is organising operational activities at the point of sale during the pilot test in Switzerland.